Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprotinin for acute respiratory distress syndrome
2025-520826-39-00Phase 3Authorised
- Sponsor
- Fundación Hospital Nacional de Parapléjicos
- Start
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute respiratory distress syndrome (ARDS) comparing Aprotinin with Placebo (2 arms). Primary endpoint: Ventilator-free days. Planned start Jun 2026; status: authorised.
02
Drugs
aprotinin
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on 2025-520826-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520826-39-00.